Entrepreneurship

Scholarship Competition – Entrepreneurship in Oncology (CEO)

CONTEXT

The Oncopole and IRICoR have joined forces to launch the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to develop their entrepreneurial skills, along with their academic skills. Thus, both organizations will offer training scholarships, as part of the new Life Sciences Entrepreneurship Development Program, created through a partnership between Montréal InVivo, Université de Montréal’s Faculty of Pharmacy and Concordia University’s John Molson Executive Centre, in collaboration with IRICoR.

 

WHY TAKE PART IN THE PROGRAM?

This practical and immersive training, the result of a joint effort between key players in life sciences from both industry and academia, will allow you to familiarize yourself with the development stages of an innovative company, from the lab to the market, through current management models that apply to both the research and the commercialization of innovation stages.

 

BRIEF OVERVIEW
  • The program includes 9 intensive 2- to 3-day modules (Friday and Saturday, once a month, classes taught in Montreal) from March, 2018, to January, 2019, in order to allow you to gradually apply the knowledge acquired to the challenges you face on a daily basis.
  • Furthermore, by taking part in this first cohort limited to about thirty candidates, you will be contributing to the progression of a tangible project with other participants from various backgrounds, thus allowing you to forge links with different players in the life science sector.

For more information, go to:

https://www.concordia.ca/jmsb/executive-education/expertise/health-management/life-sciences-entrepreneurship-development.html

 

OBJECTIVE OF THE COMPETITION (CEO)

The Oncopole and IRICoR want to ensure the training of the next generation of scientists through better tools for project management and entrepreneurial skills. Both organizations aim to identify the most promising candidates in the ecosystem and make it easier for them to get a training that meets their needs.

 

ELIGIBILITY OF APPLICANTS

PhD candidates (at least 3 years completed), Postdoctoral Fellows and Young Investigators (Research Scholars – Junior 1 and Junior 2) (prior to tenure) affiliated with a Canadian teaching or research institution at application submission, are eligible.

 

SCHOLARSHIP AMOUNT

The scholarship amount awarded to each recipient will cover the full program registration fees, namely $5,890 + taxes. Furthermore, applicants residing outside the Montreal metropolitan area could be reimbursed for part of their travel and accommodation costs related to having participated in the program.

 

TIMELINE AND EVALUATION

Applicants must fill out the form (attached or below) and send it to audrey.segret@umontreal.ca, by February 7, 2018, at 5:00pm. The applicants can also contact Audrey for any question on the competition.

Applicants will be informed of the results by March 1, 2018. Applications will be assessed according to the following scorecard:

Scoring Sections Criteria
1. Applicant information
15% 2. Research experience:
50 words – Relevance of the oncology research project
100 words – Academic distinction
100 words – Scientific communication
Activities and achievements to date
35% 3. Previous entrepreneurial experience:
300 words – Relevance of previous entrepreneurial experience (3 max.)
500 words – Demonstration of the applicant’s sense of entrepreneurship
General characteristics and skills

Entrepreneurial experience and skills demonstrated

50% 4. Motivation:
500 words – Motivation to join the program
250 words – Expectations with respect to the program
Potential shown

Alignment of program/career goals

 

FILLING OUT AND SENDING THE FORM
  • Make sure to download and save the document onto your computer in order to fill it out.
  • Please title the document as follows: Last name_application form_CEO, then send it to audrey.segret@umontreal.ca, by February 7, 2018, 5:00pm.
  • The document must be sent in PDF format.

 

APPLICANT’S COMMITMENT

By submitting his/her application, the applicant must agree:

  • To attend all sessions of the Life Sciences Entrepreneurship Development Program.
  • Following completion of the program, to provide the Oncopole and IRICoR with his/her assessment of said program and of the competition; this assessment to be done when and how the Oncopole and IRICoR deem fit (e.g. meeting, report, form, etc.).
  • To authorize the Oncopole and IRICoR to keep and to use all of the information contained in its file provided that all personal information will remain confidential.

For more information about the Life Sciences Entrepreneurship Development Program, please contact:

Valérie Lancelot-Mingot
Programs Manager
John Molson School of Business
514 848-3960
valerie.lancelot-mingot@concordia.ca

 

About the Oncopole

The Oncopole is Quebec’s hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the Fonds de recherche du Québec – Santé (FRQS) and made possible by an initial $15M investment from Merck Canada. The Oncopole’s mission is to act as a catalyst leveraging actions made by the key players in Quebec’s oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, a positive impact for the benefit of patients. For more information about Oncopole, go to: oncopole.ca

 

About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)

As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR, go to: iricor.ca